Shares of Renalytix Plc (LON:RENX – Get Free Report) were down 1.6% on Tuesday . The stock traded as low as GBX 1.80 and last traded at GBX 1.87. 194,919 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 834,957 shares. The stock had previously closed at GBX 1.90.
Renalytix Stock Performance
The company has a quick ratio of 2.42, a current ratio of 1.21 and a debt-to-equity ratio of -118.57. The company has a market cap of £8.22 million, a P/E ratio of -0.47 and a beta of 1.81. The business has a 50-day moving average price of GBX 1.82 and a two-hundred day moving average price of GBX 3.59.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Read More
- Five stocks we like better than Renalytix
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
